Welcome to DeveloGen, a biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of metabolic and endocrine disorders.

Willkommen bei DeveloGen. DeveloGen ist ein biopharmazeutisches Unternehmen, fokussiert auf die Entdeckung und Entwicklung neuer Behandlungen von Stoffwechselerkrankungen und endokrinologischen Erkrankungen.

June 19^th, 2007
DeveloGen and Teva Enter into Exclusive License Agreement for DeveloGen's Protein Kinase B Technology for the Treatment of Cancer

(62 KB)

June 14^th, 2007
DeveloGen Israel Limited ("DeveloGen"), a wholly owned subsidiary of DeveloGen AG, and Andromeda Biotech Ltd. ("Andromeda"), a newly formed wholly owned subsidiary of Clal Biotechnology Industries Ltd. ("CBI"), today announced that DeveloGen and Andromeda have completed the final agreement for an asset purchase agreement for DeveloGen's DiaPep277® program for the treatment of type 1 diabetes.

(110 KB)